Skip to main content

Table 3 Clinicopathological parameters and the expression of miR − 204-5p in LUSC. Annotation: LUSC, lung squamous cell carcinoma. The rest were the same as Table 1. a, paired sample’s t test performed to compare miR-204-5p expression between NSCLC and the controls; Independent sample’s t test processed to assess relationships between miR-30d-5p expression and the clinicopathological parameters of NSCLC. TNM, tumor, node, metastasis; b, One-way ANOVA preformed to evaluate distributive feature of miR-204-5p in three or more groups of clinicopathological parameters

From: Downregulation of hsa-microRNA-204-5p and identification of its potential regulatory network in non-small cell lung cancer: RT-qPCR, bioinformatic- and meta-analyses

Clinicopathological parameters

n

Relevant expression of miR-204-5p (2−ΔCq)

Mean ± SD

t/F-value

p-value

Tissue

LUSC

23

4.6870 ± 1.80638

-2.264a

0.029

Non-cancer

23

6.0217 ± 2.17547

Gender

Male

18

4.8556 ± 1.68041

0.844

0.408

Female

5

4.0800 ± 2.31452

Age (years)

< 60

15

4.6933 ± 1.52572

0.020

0.985

> = 60

8

4.6750 ± 2.36628

Smoke

No

12

4.8500 ± 1.72495

0.444

0.662

Yes

11

4.5091 ± 1.95931

Tumor size

<=3 cm

7

4.3857 ± 1.96759

−0.520

0.608

> 3 cm

16

4.8188 ± 1.78222

Vascular invasion

No

20

4.6150 ± 1.86471

−0.485

0.633

Yes

3

5.1667 ± 1.56950

TNM

I-II

10

4.9700 ± 2.21512

0.650

0.523

III-IV

13

4.4692 ± 1.47783

Lymph node metastasis

No

11

4.8364 ± 2.28266

0.364

0.721

Yes

12

4.5500 ± 1.32150

Pathological grading

I

0

 

0.038b

0.848

II

16

4.6375 ± 1.80032

III

7

4.8000 ± 1.95959